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Abstract
Hepatitis C virus (HCV) has a high propensity to 
establish chronic infections. Failure of HCV-infected 
individuals to activate effective antiviral immune 
responses is at least in part related to HCV-induced 
impairment of dendritic cells (DCs) that play a central 
role in activating T cell responses. Although the impact 
of HCV on DC phenotype and function is likely to 
be more prominent in the liver, major HCV-induced 
alterations are detectable in peripheral blood DCs 
(pbDCs) that represent the most accessible source of 
DCs. These alterations include numerical reduction, 
impaired production of inflammatory cytokines and 
increased production of immunosuppressive IL10. These 
changes in DCs are relevant to our understanding the 
immune mechanisms underlying the propensity of HCV 
to establish persistent infection. Importantly, the non-
invasive accessibility of pbDCs renders the analysis of 
these cells a convenient procedure that can be serially 
repeated in patient follow-up. Accordingly, the study 
of pbDCs in HCV-infected patients during conventional 
treatment with pegylated interferon and ribavirin 
indicated that restoration of normal plasmacytoid 
DC count may represent an additional mechanism 
contributing to the efficacy of the dual therapy. It also 
identified the pre-treatment levels of plasmacytoid DCs 
and IL10 as putative predictors of response to therapy. 
Treatment of chronic HCV infection is changing, as 
new generation direct-acting antiviral agents will soon 
be available for use in interferon-free therapeutic 
strategies. The phenotypic and functional analysis of 
pbDCs in this novel therapeutic setting will provide a 
valuable tool for investigating mechanisms underlying 
treatment efficacy and for identifying predictors of 
treatment response. 
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Core tip: Dendritic cells (DCs) are professional antigen-
presenting cells that play a primary role in the activation 
and coordination of primary immune responses. In 
this review we will illustrate and discuss the emerging 
understanding of DC impairment occurring in patients 
with chronic hepatitis C virus (HCV) infection and the 
impact of therapy on DCs. Particular attention will be 
paid to HCV-induced alterations of DCs in the peripheral 
blood, as the non-invasive accessibility of these cells 
renders their analysis a convenient procedure that can 
be serially repeated in patient follow-up.
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INTRODUCTION
One of the main features of the hepatitis C virus (HCV) 
is its high propensity to establish chronic infections that 
is related to impaired function and a decreased number 
of HCV-specific T cells[1,2]. Given the important role of 
dendritic cells (DCs) in activating T cell responses[3], 
DCs have become the target of investigation demons­
trating that failure of HCV­infected individuals to 
activate effective antiviral immune responses is at 
least in part the result of HCV­induced impairment 
of DC function. Because of the difficulties in gaining 
access to liver DCs, although the liver is the primary 
site for HCV replication most studies addressing DC 
involvement in chronic HCV infection have focused on 
peripheral blood DCs (pbDCs). These studies provided 
useful information on the impact of HCV on DCs, the 
contribution of DCs to the pathogenesis of hepatitis 
C, the effects of therapy on DCs and DC features 
predictive of response to treatment.
CHRONIC INFECTION WITH HEPATITIS C 
VIRUS 
Epidemiological aspects and natural history 
HCV infection has a worldwide distribution and has 
been recognized as a major cause of chronic hepatitis, 
cirrhosis and end­stage liver disease. According to 
the 2013 World Health Organization report, about 
150 million people are chronically infected by HCV 
worldwide and more than 350000 people die every 
year due to HCV­related complications[1]. 
Up to the 1990’s, the principal routes of HCV 
infection, were blood transfusion, unsafe injection 
procedures and intravenous drug use. Taken together 
these routes are estimated to be responsible for 
approximately 70% of chronic cases in developed 
countries. Currently screening of blood products for 
HCV by means of enzyme immunoassays (EIA) and 
nucleic acid testing has virtually eradicated transfusion­
associated hepatitis C. Similarly, in the developed 
world, new HCV infections are infrequently related 
to unsafe medical or surgical procedures and spread 
among the community of people using intravenous 
drugs now accounts for the vast majority of incident 
cases. Other invasive behaviors, such as tattooing 
and acupuncture with unsafe materials are also 
implicated in occasional HCV transmissions. The risk 
of perinatal and of heterosexual transmission of HCV 
is low while male homosexual activity has become an 
important transmission route in Western Countries[4]. 
Conversely, the situation is quite different in resource­
poor countries, where lack of public awareness and 
continuous use of unsafe medical tools still account for 
a considerable proportion of new HCV infections. 
HCV is a positive strand RNA virus characterized by 
high sequence heterogeneity. Seven HCV genotypes, 
numbered 1 to 7, and a large number of subtypes 
have been described[5]. Genotypes and subtypes (which 
are identified by lowercase letters), differ among 
themselves by about 30% and 20% of their sequences 
respectively. 
Acute hepatitis C is rarely severe, and symptoms 
occur in 10% to 50% of cases[4]. The incidence of acute 
HCV infection has decreased and it is about 1/100000 
per year but this figure is probably underestimated 
because it mainly refers to symptomatic patients. 
Progression to chronic infection occurs in about 
75% of cases but again, the estimate is very roughs 
mainly due to difficulties in the diagnosis of the acute 
infection[6] and possibly to difference related to the 
route of infection. For example, in a small outbreak 
of acute hepatitis C (genotype 2c) among subjects 
who took part in pharmacokinetics studies, chronicity 
occurred in less than 50% of subjects and some cases 
of very late clearance (up to 24 mo from the date 
of infection) were also described. In this latter case, 
unsafe procedures of blood sampling were supposed 
to be responsible for HCV infection[7].
Chronic hepatitis C is characterized by a variable 
degree of inflammation and with variable rates of 
fibrosis progression. Only exceptionally, HCV infection 
clear spontaneously in the chronic stage. Depending 
on the viral genotype, between 15% and 45% of 
infected cases will spontaneously resolve the infection 
within six months of infection without any treatment 
whilst the remaining proportion of cases will maintain 
the virus for years, with a risk of developing liver 
cirrhosis within 20 years up to 15%­30%[1]. On 
average, 20%­30% of patients develop cirrhosis over 
20­30 years of infection[6]. The risk of developing 
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hepatocellular carcinoma (HCC) in patients with 
HCV liver cirrhosis is approximately 1% to 5% per 
year. Patients with a diagnosis of HCC have a 33% 
probability of death during the first year of diagnosis[8]. 
Overall the standardized mortality rate in anti­HCV­
positive persons ranges from 1.6 to 4.5 and was as 
high as 25 in a recent study from Scotland[9].
Hepatitis C progression to cirrhosis is highly 
variable depending on the presence of cofactors 
capable of accelerating the fibrotic process. Proven 
cofactors for fibrosis progression include older age at 
infection, male gender, chronic alcohol consumption, 
obesity, insulin resistance and type 2 diabetes, and 
immunosuppression (such as that occurring after 
solid organ transplantation and in untreated HIV 
infection)[10]. The clinical management of these 
cofactors represents a mainstay of HCV treatment, 
especially because many of these cofactors are 
associated with poor response to clinical treatment.
Clinical management
The primary goal of HCV therapy is to cure the 
infection, which is generally associated with the 
resolution of liver disease in patients with less 
advanced disease, that is, in patients without cirrhosis. 
However, patients with cirrhosis who have eradicated 
viral infection remain at risk of severe complications, 
mainly the development of HCC[11] and therefore need 
to continue active ultrasonographic follow up for early 
detection of HCC. 
The infection is cured in more than 99% of 
patients who achieved a sustained virological response 
(SVR), defined as undetectable HCV RNA 24 wk 
after treatment completion[9]. Until recently, the only 
therapeutic option for chronic HCV infection was the 
combination of pegylated interferon (pegIFN) plus 
ribavirin (RBV), also known as dual therapy. With this 
regimen, patients infected with genotype 1 had SVR 
rates ranging from 40% in North America to 50% 
in Western Europe. Genotype 4 too, is characterized 
by low SVR rate. Higher SVR rates were achieved 
in patients infected with other HCV genotypes. For 
genotype 2, SVR rates accounted for about 80% while 
for genotypes 3, 5 and 6 the success rate appears to 
be lower. Both pegylated IFN molecules, pegylated 
IFNα2b (1.5 mcg/kg/wk) and pegylated IFNα2a (180 
mcg/wk) can be used. Ribavirin should be given at a 
weight based daily dose (15 mg/kg) for genotypes 1, 4, 
5 and 6 whereas, for genotype 2 and 3, a flat dose of 
800 mg/d is indicated[9]. 
Although they do not target a specific HCV protein 
or nucleic acid, both pegIFN and RBV exert their 
antiviral activity through induction of various antiviral 
proteins and through different immunomodulating 
actions. Dual therapy has been largely used for all 
genotypes but it is characterized by both limited 
efficacy and poor tolerability[9,12] and these limitations 
have stimulated research to explore the feasibility 
of new therapeutic tools. HCV interferon­dependent 
therapies rely on host factors such as IL28B poly­
morphism, liver fibrosis stage, and prior peg/IFN-RBV 
history to predict treatment response[13,14]. 
Recently, improvement in our knowledge of the 
molecular biology of the HCV replication life cycle led 
to the discovery of several molecules that specifically 
block various viral proteins[15,16]. These compounds 
are called direct­acting antiviral agents (DAA) and 
target different nonstructural proteins involved in 
the HCV life cycle, including the NS3/4A protease, 
the NS5B polymerase and the NS5A protein. There 
are 4 classes of DAAs: NS3/4A protease inhibitors; 
NS5B nucleos(t)ide inhibitors; NS5B nonnucleos(t)ide 
inhibitors; NS5A inhibitors[17]. The first DAAs approved 
for the treatment of chronic HCV infection were the 
protease inhibitors (PI) telaprevir and boceprevir. 
Efficacy of these two first PI generation is limited 
to genotype 1, being genotype 1a less responsive 
than genotype 1b. The addition of PI to dual therapy 
significantly improved the efficacy of treatment 
for genotype 1 HCV infection but at the expenses 
of worsened side effect profile with the potential 
for severe adverse events, mainly hematological 
complications[18­21]. 
All naive patients with compensated disease due 
to HCV should be considered for therapy. Treatment 
should not be deferred in case of significant fibrosis 
(METAVIR score F3-F4). For genotype 1 the addition 
of telaprevir or boceprevir to the dual therapy is the 
approved standard of care. Duration of therapy ranges 
between 24 and 48 wk depending on the rapidity 
of viral clearance. However, these triple­therapy 
regimens are complexes, with variable viral monitoring 
and stopping rules. All patients with cirrhosis should 
be treated for 48 wk. Only selected patients with 
contraindication to boceprevir or telaprevir and/or with 
highly likelihood of SVR should be administered dual 
therapy[9]. 
The combination of pegIFN and RBV is the approved 
standard of care for chronic hepatitis C, genotypes 2, 3, 
4, 5 and 6. Dual­treatment duration should be tailored 
to on-treatment virological response. The likelihood of 
SVR is directly proportional to the speed of HCV RNA 
disappearance. Treatment should be stopped at week 
12 if the HCV RNA decrease is less than 2 log UI/mL 
and at week 24 if HCV RNA is still detectable[9]. In 
patients with rapid virological response (undetectable 
HCV RNA at week 4), duration of treatment should 
be 24 wk but, for genotype 1 and 4, 24 wk of therapy 
may be sufficient only in the presence of low viral 
load (< 400000 UI/mL) at baseline; the remaining 
patients should be treated for 48 wk. Patients with 
later virological response should be treated for 48 wk, 
as well[9].
The protease inhibitor, Simeprevir and the nucleo-
s(t)ide polymerase inhibitor, Sofosbuvir have been the 
first DAAs approved for HCV treatment. They were 
shown to be safer and more effective compounds 
compared with interferon­based therapy. Subsequently 
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factor and inducer of pro­inflammatory responses 
(reviewed in[29,30]). Amongst its functions, IFNγ boosts 
the cytotoxic activities of CD8+ T cells and NK cells, 
favours the differentiation of Th1 cells, enhances the 
killing activities mediated by phagocytes of the innate 
immunity, upregulates the expression of both class I 
and class Ⅱ MHC molecules on by­stander cells and 
also stimulates activated B cells to perform antibody 
isotype switch towards IgG classes that are favourable 
for opsonisation and phagocytosis, complement 
activation and antibody­dependent cell cytotoxicity. 
Furthermore, besides its immune activities IFNγ can­
like the other interferons, alpha, beta and lambda-
act directly on infected cells, inducing intracellular 
genetic programs of direct antiviral response involving 
the expression of several interferon­stimulated 
genes (ISGs) that directly target viral metabolites 
suppressing viral replication. Infected cells can 
therefore be purged of the virus without undergoing 
immune-mediated killing, and by-stander cells can 
achieve an antiviral state that renders them refractory 
to infection. The production of IFNγ is facilitated by 
innate pro-inflammatory cytokines such as IL12, IL15 
and IL18, which are mainly produced by activated 
antigen­presenting cells.
IL10 and other inhibitory pathways
If the production of IFNγ develops hand­in­hand with 
and favours the control of the infection, the production 
of anti-inflammatory IL10 follows different kinetics. 
In contrast with the pro­inflammatory and antiviral 
role of IFNγ, IL10 is one of the strongest endogenous 
immune suppressing agents physiologically produced 
by multiple cell subsets of both the innate and 
the adaptive immune system, including antigen­
presenting cells (monocytes, dendritic cells) and 
subsets of antigen-specific T cells (reviewed in[31,32]). 
The physiological role of IL10 is to shut down no 
longer required immune responses, thus preventing 
continuous immune activation and immune­mediated 
tissue damage. Functionally speaking, IL10 contrasts 
several functions exerted by IFNγ, effectively 
suppressing antigen processing and presentation by 
antigen-presenting cells and T-cell-mediated antiviral 
functions, both direct and indirect. IL10 can suppress 
the production of almost all pro­inflammatory 
cytokines and chemokines[32], and can direct the 
differentiation of anergic T cells from naïve precursors, 
thus contributing to the development of impaired T-cell 
responses[33­35].
The production of IL10 can be induced in com-
bination with other immunological negative check 
points that share functional similarities, such as the 
Programmed­Death­1 (PD1) pathway. Several groups 
have shown that in patients with established chronic 
HCV infection HCV-specific T cells manifest with an 
immune exhausted phenotype[36­38] characterized by 
suppressed antigen-specific proliferation and cytokine 
production together with increased expression of PD1 
several other DAAs have also been approved and many 
other compounds from all DAA families are still under 
evaluation. Therefore, interferon-free strategies for 
the therapy of HCV chronic infection will be available 
in the near future with many advantages in terms of 
tolerability. This is the reason why many doctors and 
patients are now choosing to defer treatment rather 
than to proceed with dual or triple therapy.
IMMUNE EFFECTOR MECHANISMS IN 
THE CONTROL OF HCV INFECTION 
The role of T cells 
The mechanisms causing the high propensity of 
HCV to establish chronic infections are not clearly 
defined, but it is believed that alterations of the anti-
viral immunity play a central role in determining the 
clinical outcome of infection. Indeed, the presence 
of strong and multi-specific T cell mediated antiviral 
responses is a hallmark of positive outcome of 
infection. It has been previously shown that a higher 
proportion of subjects who spontaneously cleared 
the HCV infection in the past have T cell proliferative 
responses to HCV peptides in comparison with patients 
with established chronic infection[22,23]. Furthermore, 
the magnitude of these responses was also greater 
in past resolvers[22]. In addition to different antigen­
specific T cell proliferation profiles, different clinical 
outcomes of the HCV infections also correlate with 
different profiles of antigen-specific T cell cytokine 
production. T cells producing high amounts of IFNγ in 
response to multiple HCV antigens can be detected (1) 
in subjects with acute HCV infections as they progress 
to spontaneously clear the virus but not in subjects 
with acute HCV infection who become chronic[24]; (2) 
in subjects with past resolved HCV infection but not 
in patients with established chronic infection[23]; (3) 
in subjects with chronic HCV infection who respond 
to IFNα plus Ribavirin and pharmacologically clear 
the virus but not in those who do not respond[25]; and 
also (4) in chronic HCV treatment responders with 
faster response kinetics (fast responders) but only to a 
lesser extent in slow responders[26]. Furthermore, the 
presence of virus-specific T cell mediated responses 
can be observed even in the absence of anti­HCV 
antibodies in subjects who cleared the infection years 
before[23,27] and also in HCV­negative children born 
from HCV­positive mothers[28], where detectable HCV­
specific T cells show increased production of IFNγ 
and reduced production of IL10 in response to HCV 
peptides in comparison to T cells obtained from the 
infected mothers, revealing a potential use of antigen­
specific T cell detection as a powerful diagnostic 
marker to identify cases of viral exposure even in 
the absence of antibodies detectable with currently 
available methods.
The role of IFNγ and other cytokines
IFNγ is the most powerful T cell-derived antiviral 
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and other T-cell activation markers that act as inhibitory 
immune check points, such as T-cell immunoglobulin 
mucin-3 (TIM3), lymphocyte attivation gene-3 (LAG3), 
cytotoxic T-lymphocyte-associated protein 4 (CTLA4) 
and CD244[39]. Furthermore, antigen-specific T-cell 
exhaustion is not specific of chronic HCV infections 
only, but it can be observed during other chronic viral 
infections, including HBV[40­44] and HIV[45­47]. Monocytes 
expressing PD1 were shown to produce IL10 in 
response to PD1 engagement during HIV infections[48], 
with the consequence of suppressing HIV­specific 
immunity. Furthermore, in alcoholic liver disease 
the production of IL10 was correlated with reduced 
expression of IFNγ and increased expression of the 
immune inhibitors PD1 and TIM3 on several immune 
subsets in response to bacterial stimulation[49]. Several 
dysfunctions associated with immune exhaustion can 
be successfully reversed using blocking antibodies 
targeting these hyper­expressed immune inhibitory 
receptors and their respective ligands[45­47,50­52], and 
immunotherapeutic protocols using these antibodies 
are currently being evaluated in clinical studies for a 
plethora of medical conditions, including viral infections 
and cancer[53,54].
In the context of acute HCV infections, strong 
HCV­specific IL10 responses develop only during 
later stages of the acute infection in subjects who 
develop chronicity[24], possibly as a compensatory 
anti­inflammatory mechanism dedicated to suppress 
unwanted immune­mediated tissue damage in the 
infected livers, and are also detectable in subjects with 
established chronic infection and in treatment non­
responders[23,25]. It has also been previously shown 
that there is an inverse correlation between IL10 
production and the presence of HCV-specific T-cell 
proliferative responses in patients with established 
chronic HCV infection[22,23], supporting the hypothesis 
that effective endogenous anti­inflammatory and 
immune inhibiting responses take place in association 
with a poorer outcome of the infection[55].
The role of NK cells
Immunological events developing early on during the 
first phases of the acute infection are key in defining 
and shaping the subsequent adaptive responses. The 
innate immunological signatures in subjects with acute 
HCV infection differ in respect to their clinical outcome. 
Cytotoxic NK cells are proportionally predominant 
in comparison to CD56bright NK cells in acutely 
infected subjects who are spontaneously resolving 
the infection whilst this predominance is absent in 
patients progressing to chronicity[24,56,57]. Furthermore, 
the relocation of innate and adaptive immune cells 
into the infected liver may be compromised in 
subjects progressing to chronicity, because these 
patients produce higher concentrations of CXCL10 
antagonist in comparison to those who spontaneously 
resolve the infection as a consequence of a higher 
dipeptidyl peptidase­4 (DPP4) activity present in 
their bloodstream[24,58­61]. The role of DPP4 in skewing 
the clinical outcome of HCV infections has also been 
demonstrated anecdotally on the basis of these 
publications, in a case report of a patient with diabetes 
on the background of chronic HCV infection who was 
treated with the DPP4 inhibitor sitagliptin (a commonly 
used anti­diabetic drug) before undergoing antiviral 
treatment. During treatment with sitagliptin alone, the 
patient experienced a 2­log reduction in HCV viral load, 
which could not be ascribed to any cause other than 
the DPP4 inhibitor[62].
DENDRITIC CELLS AND CHRONIC HCV 
INFECTION 
DCs are professional antigen­presenting cells and 
have a primary role in the activation and coordination 
of primary immune responses. Different types of DCs 
exist through the body. They express different markers 
and home to different tissues; some re­circulate in the 
bloodstream[3,63­65]. Dendritic cells sense pathogen­
associated molecular patterns of bacterial, fungal 
or viral origin (PAMPs) thanks to their expression 
of several innate receptors such as TLRs and 
RLRs[3,64]. Immature DCs are primarily sampling the 
immunological milieu of the tissue where they reside. 
However, upon activation immature DCs undergo a 
transformation process that includes upregulation of 
class Ⅰ and class Ⅱ MHC molecules and co­stimulatory 
molecules such as CD80 and CD86, production of 
type­1 and type­3 interferons (IFNα, IFNβ, IFNλ), 
production of pro-inflammatory cytokines IL12, IL15, 
IL18 (amongst others), production of tissue­protecting 
IL10, and radical changes in their chemokine receptor 
and adhesion molecule profile[3,63­65]. Activated mature 
DCs migrate to the lymphoid organs, where they 
interact with and activate both naïve and experienced 
T cells. Interactions between DCs and NK cells are 
also important for the modulation of the innate 
immunity (reviewed in[66]). The induction of a pro-
inflammatory milieu locally also activates tissue­
resident fibroblasts[67­69], and the production of new 
extracellular matrix (fibrogenesis) marks the beginning 
of the healing response and the deposition of scar 
tissue. In the liver, this is associated with the activation 
of hepatic stellate cells (HSCs), which favours the 
development of fibrosis and cirrhosis, hallmarks of 
chronic liver disease[70,71].
The idea that DC functions may be impaired during 
HCV infection has been evaluated in a multiplicity of 
studies, often with conflicting results depending on the 
experimental conditions and the cohorts of patients 
studied. However, on the overall, all these studies point 
at the non­equivocal conclusion that DCs do behave 
differently in patients with hepatitis C than they do in 
healthy subjects.
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Liver dendritic cells in chronic HCV infection
As the liver is the primary site of HCV replication, 
it is conceivable that DCs would migrate into the 
infected tissues and that DC changes induced by 
the virus are prominent in the liver. Investigation of 
DCs in the liver of HCV­infected patients is indeed 
hampered by difficulties in gaining access to liver DCs. 
Therefore, our knowledge about liver DCs during HCV 
infection are limited. The few studies that investigated 
these cells demonstrated by either direct or indirect 
methods that DCs are enriched in the liver of HCV­
infected patients[72­75] (reviewed in[76,77]). Contrasting 
results have been reported regarding the reciprocal 
distribution of DC subsets in the liver[73,78]. Notably, 
the demonstration that DCs in livers from patients 
with hepatitis C localize in areas of liver necrosis[79], 
together with the experimental observation that DCs 
and T cells are together recruited within HCV-infected 
human liver slices[80], strongly support a role for DCs 
in the activation of HCV­specific immune responses. 
The mechanisms underlying DC enrichment in the liver 
of HCV­infected individuals are still poorly defined. 
Beyond an increased local recruitment, the observation 
that in vitro the migration of DCs is strongly inhibited 
by the interaction of DCs with the viral protein HCV 
E2[81] may suggest that DC entrapment within the liver 
may contribute to the process. 
Dendritic cells in the peripheral blood
pbDCs are the most accessible source of DCs. They 
can be divided into two main subsets: myeloid DCs 
(mDCs) and plasmacytoid DCs (pDCs)[3,63­65]. Neither 
of them express lineage-specific markers (CD3, CD14, 
CD16, CD19, CD20), but both of them express high 
levels of HLA­DR. mDCs are characterized by high 
expression of the integrin CD11c and the blood DC 
antigens (BDCA) 1 (CD1c) or 3 (CD141). pDCs do 
not express CD11c and BDCA1­3, but express high 
levels of the IL3 receptor (CD123), BDCA2 (CD303) 
and BDCA4 (CD304) instead[82]. Activated mDCs 
and pDCs have very distinct cytokine profiles. mDCs 
produce preferentially IL12 and IL10, whilst pDCs 
are the strongest producers of type­1 and type­3 
interferons (IFNα, IFNλ)[3,63­65]. pDCs express high 
levels of TLR3, 7-9, and are therefore highly sensitive 
to viral nucleic acids, nucleobases and ribonucleosides. 
mDCs may play a stronger role as orchestrators of 
pro­inflammatory responses, but pDCs are certainly 
strongly involved in the development of anti­viral 
responses. mDCs and pDCs can be counted and 
characterized by flow cytometry directly performed on 
peripheral blood samples[83,84].
The frequency of pbDCs in the bloodstream is 
extremely low. This has hampered the study of these 
cell populations, as high concentrations of pbDCs 
can only be obtained starting from high volumes of 
peripheral blood. However, DCs can be successfully 
differentiated from peripheral blood monocytes 
stimulated with either IL4 or IFNα in the presence 
of GM­CSF (monocyte­derived DCs, moDCs)[85], and 
this has allowed researchers to bypass the issue 
of low availability in the peripheral blood and has 
granted them a useful in vitro model for the functional 
characterization of these cells.
Impairment of peripheral blood DCs in chronic HCV 
infection
Several studies investigated the impact of HCV 
infection on DCs by analyzing pbDCs. The main 
findings are illustrated in Figure 1, that recapitulates 
the current view on pbDCs involvement in HCV 
pathogenesis. In particular, most studies reported a 
numerical reduction of pbDCs in patients with chronic 
HCV infection, yet with some conflicting results on 
whether either mDCs or pDCs or both subsets are 
affected[22,73,86­92]. Although pDCs are undoubtedly 
specialized in antiviral defenses, the reduction of 
mDCs may be relevant to HCV infection as well, as 
mDCs through IL12 production and the subsequent 
polarization of Th1 responses may contribute to the 
activation of cellular immunity. However, the reason 
for pbDC reduction is still unclear. pbDC reduction has 
been reported to be associated with the degree of liver 
inflammation[93], possibly suggesting that the reduction 
of DCs in the peripheral blood may be due, at least in 
part, to an enhanced recruitment of these cells in the 
inflamed liver. pbDC reduction has also been reported 
to be more pronounced in patients infected with 
HCV genotype 2[22], but not correlated with the viral 
load[22,73,86,88,91], suggesting that multiple viral and non 
viral mechanisms may directly and indirectly contribute 
to the decrease of mDCs and pDCs in the circulation. 
Notably, our previous demonstration that the number 
of pbDCs is unaffected in healthy HCV­seropositive 
patients who underwent spontaneous resolution of 
their HCV infection[22] clearly indicate that active HCV 
infection is needed in order to determine a reduction of 
pbDCs.
The functional assessment of pbDCs could also 
demonstrate that pbDCs from patients with chronic 
HCV infection are functionally impaired. Several studies 
demonstrated indeed that, upon stimulation with TLR 
ligands, viruses or interaction with T cells, both mDCs 
and pDCs from HCV­infected patients have impaired 
production of pro-inflammatory and anti-inflammatory 
cytokines compared with healthy controls. Due to the 
important role played by pDCs and IFN in antiviral 
immune responses, many Authors investigated the 
ability of pDCs to produce IFNα in response to distinct 
TLR ligands, with impaired IFN production observed in 
HCV­infected patients by some Authors[87,88,90,91], but 
not by others[89,94,95]. Moreover, mDCs from patients 
with chronic HCV infection were demonstrated to 
be characterized by impaired production of IL12, 
that in some cases was associated with impaired 
allostimulatory activity, and increased production 
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of IL10[22,87,88,96,97]. All together, these observations 
indicate that, despite discrepancies among studies 
possibly due to differences in the patient cohorts and 
the experimental procedures, the analysis of circulating 
pbDCs can detect numerical and functional alterations 
of DCs occurring during HCV infection.
Similarly to pbDCs, also moDCs have been 
demonstrated to be impaired in HCV­infected patients, 
with reduced IL12 production, reduced allostimulatory 
activity and increased IL10 production reported in 
many studies but not confirmed in others, as reviewed 
elsewhere[92]. moDCs have been suggested to be less 
representative of in vivo functions compared with 
pbDCs, as discussed elsewhere[22]. Nevertheless, 
they have proven to be a very useful model for the 
study of DC functions. Yet, they have been largely 
used for studying the effects of cell culture­adapted 
strains of HCV on DCs and they provided insight 
into the molecular interactions of recombinant HCV 
proteins with DCs in vitro (reviewed in[98]). Although 
the mechanisms whereby HCV affects DC function 
still remain largely elusive, the effects of many 
viral components and proteins on DCs have been 
defined[99].
Effects of therapy with pegIFN plus RBV on peripheral 
blood DCs
As reported above, the analysis of pbDCs from patients 
with chronic HCV infection allows the detection of 
DC defects that can be relevant to the inadequate 
activation of immune responses leading to HCV 
persistence. Until recently the only therapeutic option 
for chronic HCV infection was the dual therapy with 
pegIFN plus RBV that achieved a sustained SVR only 
in part of the patients. For these reasons, several 
studies investigated the effects of dual therapy on 
pbDC number and functions according to virological 
response, in order to define the impact of treatment 
on DCs and to possibly identify correlates of clinical 
response. In most of the studies, the standard 
treatment with pegIFN plus RBV for 24 or 48 wk 
induced an increase of the number of pDCs in patients 
who achieved a SVR[100­102]. An early increase of 
pDCs during treatment was considered a correlate of 
favourable response in two studies[100,103]. pDC increase 
was accompanied by mDC increase in one study[102]. 
Only one study reported no variation in the number 
of pbDC subsets during treatment follow­up[104], but 
the reasons for this discrepancy are not evident. In 
this context, we can add our evidence supporting the 
impact of the dual therapy on pDCs. We analyzed 
pbDCs in a cohort of 14 HCV­infected patients (11 
males, 3 females; mean age 49 years, range 29­68 
years) undergone standard treatment with pegIFN 
and RBV for 24 or 48 wk depending on the viral 
genotype. pbDCs were analyzed before, after 1 mo 
of treatment, at the end of therapy and 6 mo after 
treatment completion. pbDCs analysis was performed 
by flow cytometry as previously described[22], in order 
to assess DC count, subset distribution, expression of 
activation/maturation markers (CD80, CD86, CD40, 
CD83), expression of molecules involved in HCV 
entry (CD81, DC-SIGN) and production of cytokines 
(IL12 and IL10). As shown in Figure 2, we observed 
that pegIFN and RBV treatment restored correct 
proportions of pDCs in SVR patients by inducing a 
rapid and progressive increase of these cells that was 
observed after 1 mo of treatment, further increased 
at the end of treatment and persisted after the end 
of treatment. SVR patients showed higher pDC levels 
than non­SVR at any time point. pegIFN and RBV 
treatment also induced a transient increase of IL12 
production by pbDCs, that was observed after 1 mo 
of treatment but decreased thereafter, and that was 
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Figure 1  Summary of the hepatitis C virus-associated alterations of dendritic cells detectable in the peripheral blood. Patients with chronic hepatitis C 
undergo changes in the number and function of both myeloid dendritic cells (mDCs) and plasmacytoid DCs (pDCs) that may be relevant to the pathogenesis of 
chronic HCV infection. In particular, several Authors demonstrated that pDCs, which are specialized in antiviral immune responses, are decreased in HCV-infected 
patients and are endowed with a reduced ability to produce interferon (IFN). mDCs, that contribute to the activation of cellular immunity through the production of 
interleukin (IL)12, are decreased as well and characterized by reduced production of IL12 and increased production of the immunosuppressive cytokine IL10. These 
last functional defects are shared by monocyte-derived DCs that are also endowed with decreased ability to activate T cells. All references are reported in the text.
Crosignani A et al . pbDCs in follow-up of HCV-infected patients
more pronounced in SVR than non-SVR patients. The 
other pbDC parameters were not affected by the dual 
therapy. Because of the role played by chemokines 
and chemokine receptors in regulating DC migration, 
Mengshol and coll. also investigated the expression 
of CXCR3 and CXCR4 demonstrating that these 
molecules, upregulated on pbDCs at baseline, are 
normalized by pegIFN plus RBV, as well[101].
The effects of therapy have also been assessed 
on moDCs, in order to investigate the mechanisms 
responsible for the impaired stimulation of T cells by 
DCs from HCV­infected patients. In an elegant cross­
over study involving chronic HCV patients undergoing 
anti­viral treatment with pegIFN and RBV[105], 
peripheral blood DCs and T cells were independently 
purified from the same patient at two time points: 
baseline (BL), with high serum HCV viral load, and 
treatment week 12 (TW12), with pharmacologically 
reduced serum HCV viral load. Co­cultures of 
autologous T cells and DCs were prepared using all 
four possible combinations from each subject (BL 
DCs plus BL T cells or TW12 T cells, and TW12 DCs 
plus BL T cells or TW12 T cells) and DC-induced T cell 
responses were measured in order to ascertain the role 
of DCs or T cells in the context of altered HCV-specific 
responses. The study showed that the measurable 
reduction in T-cell responses was not dependent on 
the T cells used, but it was always only the use of 
DCs obtained at baseline, with high viral presence, 
which was associated with low T cell immunity. 
Conversely, DCs obtained at the later time point, after 
pharmacological viral clearance, were able to stimulate 
with similar higher efficiency both BL T cells and TW12 
T cells.
Peripheral blood DCs as predictors of response to 
treatment
Predicting the outcome of a treatment that is admini­
stered to a patient is a goal for both patients and 
physicians. Accordingly, the identification of pbDC 
parameters measured at baseline or at the beginning 
of treatment that may predict SVR or non­SVR was 
a primary aim of the studies that analyzed pbDCs in 
HCV­infected patients treated with pegIFN and RBV. 
Notably pDCs, whose increase represented the most 
relevant treatment­induced pbDC modification, also 
resulted good predictors of response in two studies, 
where higher levels of pDCs during the first weeks of 
treatment were associated with SVR[100,103]. High levels 
of pDCs at baseline was a predictor of SVR in our cohort 
of patients, as well, independent from other clinical 
features including viral genotype and viral load (Figure 
2). An increased pbDC production of IL­10 at baseline 
has been reported as non­SVR predictor by Liang and 
coll[102], and confirmed in our cohort of patients. 
CONCLUSION
Although the impact of HCV on DC phenotype and 
function is likely to be more prominent in the liver 
as it is primarily infected by the virus, nevertheless 
several HCV­induced alterations are detectable in 
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Figure 2  Effects of dual therapy with pegylated interferon and ribavirin on 
peripheral blood dendritic cells. The treatment induced a rapid, progressive 
and persistent increase of plasmacytoid dendritic cells (pDCs) in sustained 
virological response (SVR) but not in non-SVR patients. The frequency of 
pDCs was higher in SVR than non-SVR patients at all the time points. pegIFN 
and RBV treatment also induced a transient increase of peripheral blood DC 
production of interleukin (IL)12, that was observed after 1 mo of treatment but 
decreased thereafter, and that was more pronounced in SVR than non-SVR 
patients. IL10 production showed a similar trend and tended to be higher in 
non-SVR patients. a and b: p < 0.05 and p < 0.01, respectively, any time vs 
t0 within each group, as assessed by Wilcoxon signed rank test; c: p < 0.05, 
SVR vs non-SVR, as assessed by Mann-Whitney test. t0: Before treatment; 
t1: After 1 mo of treatment; t2: At the end of treatment; t3: 6 mo after treatment 
completion.
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pbDCs that represent the most accessible source of 
DCs. These alterations include numerical reduction, 
impaired production of IL12 and IFNα, impaired 
allostimulatory activity and increased production 
of immunosuppressive IL10. Despite somehow 
controversial because variably observed among 
different cohorts of patients, these HCV­associated 
DC features are relevant to our understanding the 
immune mechanisms underlying the propensity of 
HCV to establish persistent infection. Importantly, 
the non­invasive accessibility of pbDCs renders the 
analysis of these cells a convenient procedure that can 
be serially repeated in patient follow­up. Accordingly, 
the study of pbDCs in HCV­infected patients during 
conventional treatment with pegIFN and RBV indicated 
that restoration of normal pDC count may represent a 
further novel mechanism contributing to the efficacy 
of the dual therapy. It also identified pDCs and 
IL10 as putative predictors of response to therapy. 
Treatment of chronic HCV infection is changing, as new 
generation direct­acting antivirals will soon be available 
for use in interferon-free therapeutic strategies. The 
phenotypic and functional analysis of pbDCs in this 
novel therapeutic setting will provide a valuable tool 
for investigating mechanisms underlying treatment 
efficacy and for identifying predictors of treatment 
response. 
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